| 1 |
34816484 | Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity. | 2022 Jan |
1 |
| 2 |
34837846 | High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. | 2022 Jan |
1 |
| 3 |
35057108 | BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia. | 2022 Jan 17 |
1 |
| 4 |
35399514 | c-Abl Activation Linked to Autophagy-Lysosomal Dysfunction Contributes to Neurological Impairment in Niemann-Pick Type A Disease. | 2022 |
1 |
| 5 |
35551463 | BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. | 2022 May 13 |
1 |
| 6 |
33155931 | Effect of Dasatinib on Genes Related to Mitotic Catastrophe Pathway in Chronic Myeloid Leukemia Cells. | 2021 |
1 |
| 7 |
33618586 | Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies. | 2021 Apr |
2 |
| 8 |
33748144 | The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach. | 2021 |
1 |
| 9 |
33772839 | High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma. | 2021 Aug |
1 |
| 10 |
33903307 | H396P mutation in chronic myeloid leukaemia patient on nilotinib - A case report. | 2021 Apr |
2 |
| 11 |
34238254 | Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA). | 2021 Jul 8 |
1 |
| 12 |
34262462 | Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia. | 2021 |
1 |
| 13 |
34422550 | Molecular, Cytogenetic, and Hematological Analysis of Chronic Myeloid Leukemia Patients and Discovery of Two Novel Translocations. | 2021 |
1 |
| 14 |
34508625 | ABL1 and Cofilin1 promote T-cell acute lymphoblastic leukemia cell migration. | 2021 Oct 12 |
1 |
| 15 |
34673444 | Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients. | 2021 Dec |
1 |
| 16 |
34884309 | Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells. | 2021 Nov 29 |
1 |
| 17 |
34959482 | The TKI Era in Chronic Leukemias. | 2021 Dec 20 |
1 |
| 18 |
34984204 | A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience. | 2021 Dec |
1 |
| 19 |
31925328 | A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein. | 2020 Jan 9 |
1 |
| 20 |
31999850 | Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. | 2020 Apr 1 |
1 |
| 21 |
32279331 | Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. | 2020 Jul |
1 |
| 22 |
32291831 | Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy. | 2020 Jul |
1 |
| 23 |
32299471 | α-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment. | 2020 Apr 16 |
1 |
| 24 |
32354950 | Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report. | 2020 May-Jun |
2 |
| 25 |
32654459 | [Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia]. | 2020 Jun 14 |
1 |
| 26 |
32655840 | Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib. | 2020 Jun 30 |
2 |
| 27 |
32667912 | Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. | 2020 Jul |
1 |
| 28 |
32764164 | Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population. | 2020 Aug 4 |
1 |
| 29 |
32899072 | Nilotinib-induced liver injury: A case report. | 2020 Sep 4 |
1 |
| 30 |
33122628 | Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling. | 2020 Oct 29 |
1 |
| 31 |
33369447 | Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. | 2020 Dec 1 |
3 |
| 32 |
30332954 | Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance. | 2019 |
1 |
| 33 |
30547682 | Nilotinib in the treatment of chronic myeloid leukemia. | 2019 Mar |
1 |
| 34 |
30692753 | Anticancer Drugs for Parkinson's Disease: Is It a Ray of Hope or Only Hype? | 2019 Jan-Mar |
1 |
| 35 |
30906562 | Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease. | 2019 Apr |
1 |
| 36 |
30971653 | [The mechanisms of taxodione-induced apoptosis in BCR-ABL-positive leukemia cells]. | 2019 |
1 |
| 37 |
30985724 | Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia. | 2019 Apr |
2 |
| 38 |
31217480 | Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. | 2019 Jul |
2 |
| 39 |
31250767 | The Perplexity of Synergistic Duality: Inter-molecular Mechanisms of Communication in BCR-ABL1. | 2019 |
1 |
| 40 |
31396300 | Reactive Oxygen Species Are Involved in the Development of Gastric Cancer and Gastric Cancer-Related Depression through ABL1-Mediated Inflammation Signaling Pathway. | 2019 |
1 |
| 41 |
29325229 | Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance. | 2018 Mar |
2 |
| 42 |
29334667 | Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects. | 2018 Mar |
2 |
| 43 |
29385210 | ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. | 2018 |
1 |
| 44 |
29434033 | PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. | 2018 May 17 |
1 |
| 45 |
29435021 | Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib. | 2018 Mar |
1 |
| 46 |
29468363 | The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells. | 2018 May |
4 |
| 47 |
29807053 | c-Abl phosphorylation of Yin Yang 1's conserved tyrosine 254 in the spacer region modulates its transcriptional activity. | 2018 Sep |
1 |
| 48 |
29897434 | The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model. | 2018 Jul 1 |
1 |
| 49 |
29945329 | Interferon-α Based Individualized Treatment of a High Risk Chronic Myelogenous Leukemia Patient Harboring T315I Mutation. | 2018 Jun 1 |
2 |
| 50 |
30121665 | Successful Use of Nilotinib in the Therapy of a Patient with a Chemoresistant Relapse of BCR-ABL1-Like Phenotype Acute Lymphoblastic Leukemia. | 2018 |
1 |